Lv3
220 积分 2022-08-23 加入
Angiogenesis
5小时前
已完结
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
8小时前
已完结
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
8小时前
已完结
Two Phase 3 Trials of Baricitinib for Alopecia Areata
10天前
已完结
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
10天前
已完结
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity
14天前
已完结
A gain-of-function variation in PLCG1 causes a new immune dysregulation disease
15天前
已完结
Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas
16天前
已关闭
A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase2atrial
16天前
已完结
Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas
16天前
已完结
皖公网安备34019202002308
